With FAP beingmainly employed in nuclear medicine as a target for PET agents, furtherstrategies to consider may involve a different FAP-inhibitor targetingmoiety or a different FAP-targeting approach, such as a peptide toimprove the tumor-to-background ratio for fluorescence imaging applications. The gene discussed is FAP; the disease is neoplasm.